Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Aims for Passage of Bill to Amend PAL during Extraordinary Diet Session This Autumn
July 1, 2013
- Study Group Approves Guidelines for Use of Medical Information Database During Trial Period
June 28, 2013
- Cost-Effective Assessment for Medical Devices Presented at CSIMC Subcommittee; Reps Say They Want Examples for Pharmaceuticals Too
June 27, 2013
- MHLW Maps Out New Vision for Pharma Industry; Research-Based Makers Will See “Survival of the Fittest,” It Says
June 27, 2013
- HSC’s Vaccination Policy Committee Approves Switch to 13-Valent Pediatric Pneumococcal Vaccine
June 26, 2013
- Patients Would Like to See Their Drug Costs Reduced by Half; Further Reductions in Generic Drug Prices to Become a Topic: Pharmaceutical Management Director Chikazawa
June 25, 2013
- LDP Election Platform Targets 16 Trillion Yen Healthcare Market in 2020
June 24, 2013
- 47 Products Including an AG of Allegra, but not That of Livalo, Added to NHI Price List in Latest Generic Listing
June 24, 2013
- First Generics for 5 Products Including Prograf, TS-1 Added to NHI Drug Price List
June 24, 2013
- FPMAJ May Find it Difficult to Compile Unified Statement of Views on TPP Talks Due to Disagreement among Original and Generic Drug Makers
June 24, 2013
- MHLW to Resume Inviting Requests for Development of Unapproved Drugs, Indications; No Deadline Set This Time
June 20, 2013
- MHLW to Quickly Compile Studies on Reported HPV Vaccine Adverse Events, Give Clear Explanation to Public: Minister Tamura
June 20, 2013
- Top Priorities for Next Midterm Plan to Include Greater Sophistication in Review and Consultation: PMDA
June 20, 2013
- MHLW to Temporarily Withdraw Recommendation of Preventive Cervical Cancer Vaccinations
June 18, 2013
- PMDA Building “Database on Unapproved Drugs” to Accelerate Elimination of Drug Lag
June 18, 2013
- Cabinet Approves PM Abe’s Growth Strategy, Regulatory Reform Plan
June 17, 2013
- Council to Discuss Problem of Prolonged Delivery Price Negotiations at Meeting on June 27
June 17, 2013
- Pharmaceutical Affairs Council Approves Revised Draft Plan to Reduce Manufacturing Costs of Blood Products
June 17, 2013
- CSIMC’s Expert Subcommittee on NHI Drug Pricing Affairs to Hold Hearings for Drug Pricing Organization at Next Meeting in July
June 14, 2013
- CSIMC Approves Plans for FY2013 Market Price Survey of Similar Size as 2 Years Ago
June 14, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…